Biogen Reports Q3 Earnings Beat and Increases FY26 Financial Outlook
Biogen (BIIB) reported third-quarter financial results that exceeded both top-line and bottom-line analyst expectations. The company posted non-GAAP earnings per share of $2.62, surpassing estimates by $0.63, while revenue reached $2.8 billion, a 10.2% increase year-over-year that beat projections by $170 million. A significant driver of this growth was the company's Growth Portfolio, which generated $1.26 billion in revenue—a 49% year-over-year surge. This segment now accounts for 63% of Core Pharmaceutical revenue and benefited from the first full quarter contribution following the acquisition of Apellis.
Topics: acquisition impact earnings beat revenue growth
Read the full article at Seeking Alpha
Part of the story Chemours Reports Q3 2026 Growth Driven by Titanium Technologies and AI Infrastructure Demand (16 articles)